Sulfasalazine


Description

A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopo...

Read more

Pharmacology

Indication

For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.

Pharmacodynamic

Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumato... Read more

Mechanism of action

The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyrid... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

7.5 ± 1.6 L

Clearance

1 L/h [IV administration]

Half life

5-10 hours

Route of elimination

The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with... Read more

Toxicity

Information currently not available.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Reversible oligospermia US
  • Kind: experimental
    • Percent: 33%
  • Clinical Trial
    Gastric Distress US
  • Kind: experimental
    • Percent: 33%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 33%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 33%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 33%
  • Clinical Trial
    Anorexia US
  • Kind: experimental
    • Percent: 33%
  • Clinical Trial
    Cyanosis US
  • Kind: experimental
    • Percent: ≤3%
  • Clinical Trial
    Heinz body anemia US
  • Kind: experimental
    • Percent: ≤3%
  • Clinical Trial
    Hemolytic Anemia US
  • Kind: experimental
    • Percent: ≤3%
  • Clinical Trial
    Methemoglobinemia US
    Clinical Trial
    Hypoprothrombinemia US
    Clinical Trial
    Thrombocytopenia US
    Clinical Trial
    Purpura US
    Clinical Trial
    Megaloblastic anemia US
    Clinical Trial
    Leukopenia US
    Clinical Trial
    Agranulocytosis US
    Clinical Trial
    Aplastic Anemia US
    Clinical Trial
    Anaphylaxis US
    Clinical Trial
    DRESS US
    Clinical Trial
    Lyell’s syndrome US
    Clinical Trial
    Exfoliative dermatitis US
    Clinical Trial
    Stevens-Johnson Syndrome US
    Clinical Trial
    Myelodysplastic Syndrome US
    Clinical Trial
    Congenital neutropenia US
    Clinical Trial
    Pruritus US
    Clinical Trial
    Fever US
    Clinical Trial
    Skin Rash US
    Clinical Trial
    Urticaria US
    Clinical Trial
    Hepatic necrosis US
    Clinical Trial
    Hepatic necrosis US
    Clinical Trial
    Hepatitis US
    Clinical Trial
    Lupus erythematosus-like syndrome US
    Clinical Trial
    Polyarteritis Nodosa US
    Clinical Trial
    Allergic myocarditis US
    Clinical Trial
    Pericarditis US
    Clinical Trial
    Pericarditis US
    Clinical Trial
    Pleuritis US
    Clinical Trial
    Fibrosing alveolitis US
    Clinical Trial
    Vasculitis US
    Clinical Trial
    Pneumonitis US
    Clinical Trial
    Pneumonitis US
    Clinical Trial
    Interstitial Lung Disease US
    Clinical Trial
    Serum sickness syndrome US
    Clinical Trial
    Diarrhea US
    Clinical Trial
    Abdominal Pains US
    Clinical Trial
    Impaired digoxin absorption US
    Clinical Trial
    Stomatitis US
    Clinical Trial
    Bloody diarrhea US
    Clinical Trial
    Impaired folic acid absorption US
    Clinical Trial
    Hepatic Failure US
    Clinical Trial

    Contraindications

    • Regions: US
    • Patient Conditions:
        • Name: Porphyria
        • Drugbank Id: DBCOND0008396
    • Regions: US
    • Patient Conditions:
        • Name: Intestinal or urinary obstruction
        • Drugbank Id: DBCOND0108011

    Food Interactions

    • May take Vitamin D.
    • Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication.
    • Take with food.

    Interactions

    Type in a drug name to check for interaction with Sulfasalazine

    The serum concentration of (6R)-Folinic acid can be decreased when it is combined with Sulfasalazine.
    The serum concentration of (6S)-5,6,7,8-tetrahydrofolate can be decreased when it is combined with Sulfasalazine.
    The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with (R)-warfarin.
    The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with (S)-Warfarin.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 1-benzylimidazole.
    The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 2-Methoxyethanol.
    Sulfasalazine may increase the hypoglycemic activities of 2,4-thiazolidinedione.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
    The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with 4-hydroxycoumarin.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 4-Methoxyamphetamine.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with 5-methoxy-N,N-dimethyltryptamine.
    The serum concentration of 5-methyltetrahydrofolic acid can be decreased when it is combined with Sulfasalazine.
    The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
    Sulfasalazine may decrease the excretion rate of Abacavir which could result in a higher serum level.
    The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Abatacept.
    The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Abciximab.
    The risk or severity of hypertension can be increased when Sulfasalazine is combined with Abediterol.

    References

      Information currently not available.

    Recent Questions